

Novel therapeutic targets on the horizon for lung cancer

Lancet Oncology, The
17, e347-e362

DOI: [10.1016/s1470-2045\(16\)30123-1](https://doi.org/10.1016/s1470-2045(16)30123-1)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Emerging therapeutic agents for lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 138.	6.9	77
2	Graphene Oxide Induced Perturbation to Plasma Membrane and Cytoskeletal Meshwork Sensitize Cancer Cells to Chemotherapeutic Agents. <i>ACS Nano</i> , 2017, 11, 2637-2651.	7.3	110
3	Sample types applied for molecular diagnosis of therapeutic management of advanced non-small cell lung cancer in the precision medicine. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, 1817-1833.	1.4	13
4	Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway. <i>Lung Cancer</i> , 2017, 106, 115-124.	0.9	22
5	CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer. <i>Lung Cancer</i> , 2017, 113, 121-127.	0.9	14
6	Src-dependent EGFR transactivation regulates lung inflammation via downstream signaling involving ERK1/2, PI3K/Akt and NF κ B induction in a murine asthma model. <i>Scientific Reports</i> , 2017, 7, 9919.	1.6	55
7	On the "TRAIL" of a Killer: MMP12 in Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 262-264.	2.5	5
8	Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1679-1686.	0.5	30
9	Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. <i>Scientific Reports</i> , 2017, 7, 17530.	1.6	53
10	Exhaustive preoperative staging increases survival in resected adrenal oligometastatic non-small-cell lung cancer: a multicentre study. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 698-703.	0.6	14
11	ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer. <i>Clinical Epigenetics</i> , 2017, 9, 60.	1.8	15
12	Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art. <i>European Journal of Radiology</i> , 2017, 86, 297-307.	1.2	222
13	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. <i>Theranostics</i> , 2017, 7, 4753-4762.	4.6	25
14	Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 103055-103062.	0.8	47
15	The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 682.	2.2	64
16	Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cells. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 2531-2551.	3.3	66
17	PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2017, 9, E384-E386.	0.6	17
18	Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 12-17.	1.8	3

#	ARTICLE	IF	CITATIONS
19	Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade. <i>Journal of Clinical Oncology</i> , 2017, 35, 2735-2736.	0.8	4
20	Predictive factors for treatment response using dual-energy computed tomography in patients with advanced lung adenocarcinoma. <i>European Journal of Radiology</i> , 2018, 101, 118-123.	1.2	17
21	A strategy to analyse activity-based profiling of tyrosine kinase substrates in OCT-embedded lung cancer tissue. <i>Analytical Biochemistry</i> , 2018, 547, 77-83.	1.1	1
22	KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e489-e501.	1.1	32
23	Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3073-3085.	1.6	23
24	Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology. <i>Cancer Investigation</i> , 2018, 36, 37-58.	0.6	15
25	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774501.	1.4	101
26	ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway. <i>Oncology Reports</i> , 2018, 39, 2892-2898.	1.2	32
27	Acetyl-macrocalin B, an ent-kaurane diterpenoid, initiates apoptosis through the ROS-p38-caspase 9-dependent pathway and induces G2/M phase arrest via the Chk1/2-Cdc25C-Cdc2/cyclin B axis in non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 609-621.	1.5	16
28	Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA). <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 220-228.	1.4	59
29	TGF β 2 pathway inhibition in the treatment of non-small cell lung cancer. , 2018, 184, 112-130.		85
30	Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S13-S18.	1.3	1
31	Regulation Mechanism of MicroRNAs in Non-Small Cell Lung Cancer. <i>Current Pharmaceutical Design</i> , 2018, 23, 5973-5982.	0.9	5
32	Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy. <i>Drug Delivery</i> , 2018, 25, 1932-1942.	2.5	34
33	Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 5178-5183.	0.6	2
34	Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy. <i>Cancer Cytopathology</i> , 2018, 126, 860-871.	1.4	11
35	Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. <i>Oncotarget</i> , 2018, 9, 26226-26242.	0.8	14
36	Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 1329-1340.	0.9	7

#	ARTICLE	IF	CITATIONS
37	Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. <i>Oncotarget</i> , 2018, 9, 11805-11815.	0.8	9
38	Design, synthesis, and evaluation of chalcone analogues incorporate α,β -Unsaturated ketone functionality as anti-lung cancer agents via evoking ROS to induce pyroptosis. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 1395-1405.	2.6	47
39	Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study. <i>Journal of Translational Medicine</i> , 2018, 16, 138.	1.8	16
40	Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. <i>Oncotarget</i> , 2018, 9, 20134-20155.	0.8	46
41	SNCA Is a Functionally Low-Expressed Gene in Lung Adenocarcinoma. <i>Genes</i> , 2018, 9, 16.	1.0	44
42	MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 195.	3.5	20
43	Chemotherapy of malignancy. , 2018, , 631-656.		1
44	Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2019, 20, 3821.	1.8	116
45	ILF2 promotes anchorage independence through direct regulation of PTEN. <i>Oncology Letters</i> , 2019, 18, 1689-1696.	0.8	6
46	<p>Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7707-7719.	0.9	45
47	Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e196879.	2.8	161
48	TFAP2A Induced KRT16 as an Oncogene in Lung Adenocarcinoma via EMT. <i>International Journal of Biological Sciences</i> , 2019, 15, 1419-1428.	2.6	44
49	Exploiting ING2 Epigenetic Modulation as a Therapeutic Opportunity for Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 1601.	1.7	8
50	Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. <i>Theranostics</i> , 2019, 9, 7122-7139.	4.6	38
51	Ang-(1-7)/ MAS1 receptor axis inhibits allergic airway inflammation via blockade of Src-mediated EGFR transactivation in a murine model of asthma. <i>PLoS ONE</i> , 2019, 14, e0224163.	1.1	16
52	ADAM17: An Emerging Therapeutic Target for Lung Cancer. <i>Cancers</i> , 2019, 11, 1218.	1.7	57
53	Transfer of Extracellular Vesicle-Associated-RNAs Induces Drug Resistance in ALK-Translocated Lung Adenocarcinoma. <i>Cancers</i> , 2019, 11, 104.	1.7	22
54	<p>Abietic acid suppresses non-small-cell lung cancer cell growth via blocking IKK β /NF- κ B signaling</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4825-4837.	1.0	36

#	ARTICLE	IF	CITATIONS
55	Cucurbitacin E inhibits the Yes-associated protein signaling pathway and suppresses brain metastasis of human non-small cell lung cancer in a murine model. <i>Oncology Reports</i> , 2019, 42, 697-707.	1.2	19
56	Methionine is a metabolic dependency of tumor-initiating cells. <i>Nature Medicine</i> , 2019, 25, 825-837.	15.2	226
57	Schizandrin A enhances the efficacy of gefitinib by suppressing IKK β /NF- κ B signaling in non-small cell lung cancer. <i>European Journal of Pharmacology</i> , 2019, 855, 10-19.	1.7	21
58	Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 447-453.	1.9	17
59	miR-497-5p inhibits tumor cell growth and invasion by targeting SOX5 in non-small cell lung cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 10587-10595.	1.2	47
60	Efficacy of carboplatin plus S-1 for the treatment of non-small cell lung cancer. <i>Medicine (United States)</i> 2019; 98(14):e16707. doi:10.1097/MD.0000000000001670	0.4	0
61	Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer. , 2019, 194, 59-72.		45
62	Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review. <i>BMC Cancer</i> , 2019, 19, 52.	1.1	5
63	Interleukin-33 and ST2 Signaling in Tumor Microenvironment. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 61-71.	0.5	29
64	Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer. <i>Journal of Cancer Education</i> , 2020, 35, 345-351.	0.6	3
65	The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis. <i>Carcinogenesis</i> , 2020, 41, 527-538.	1.3	24
66	Knockdown of lncRNA ZFAS1 suppressed non-small cell lung cancer progression via targeting the miR-150-5p/HMGA2 signaling. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3814-3824.	1.2	26
67	Systematic evaluation of PAXgene tissue fixation for the histopathological and molecular study of lung cancer. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 40-54.	1.3	8
68	Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 372-390.	2.5	19
69	Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma. <i>Thoracic Cancer</i> , 2020, 11, 346-352.	0.8	13
70	<p>The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11351-11358.	0.9	3
71	BMI1-Mediated Pemetrexed Resistance in Non-Small Cell Lung Cancer Cells Is Associated with Increased SP1 Activation and Cancer Stemness. <i>Cancers</i> , 2020, 12, 2069.	1.7	20
72	Combined Treatment of Non-Small-Cell Lung Cancer Using Shenyi Capsule and Platinum-Based Chemotherapy: A Meta-Analysis and Systematic Review. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-12.	0.5	5

#	ARTICLE	IF	CITATIONS
73	<p><p>Puerarin Enhances the Anti-Tumor Effect of Cisplatin on Drug-Resistant A549 Cancer in vivo and in vitro Through Activation of the Wnt Signaling Pathway</p></p>. Cancer Management and Research, 2020, Volume 12, 6279-6289.	0.9	6
74	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. , 2020, 8, e000469.		59
75	PNO1, which is negatively regulated by miR-340-5p, promotes lung adenocarcinoma progression through Notch signaling pathway. Oncogenesis, 2020, 9, 58.	2.1	20
76	The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC). Cancers, 2020, 12, 1361.	1.7	39
77	RNF115-mediated ubiquitination of p53 regulates lung adenocarcinoma proliferation. Biochemical and Biophysical Research Communications, 2020, 530, 425-431.	1.0	14
78	Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. Frontiers in Immunology, 2020, 11, 1173.	2.2	26
79	Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study. Lancet Oncology, The, 2020, 21, 723-732.	5.1	22
80	Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients â€œ A systematic review. Critical Reviews in Oncology/Hematology, 2020, 153, 103035.	2.0	5
81	Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Lung Cancer, 2020, 147, 83-90.	0.9	12
82	High ubiquitin conjugating enzyme E2 T mRNA expression and its prognostic significance in lung adenocarcinoma. Medicine (United States), 2020, 99, e18543.	0.4	7
83	SOX2â€in-induced upregulation of lncRNA LINC01561 promotes nonâ€smallâ€cell lung carcinoma progression by sponging miRâ€760 to modulate SHCBP1 expression. Journal of Cellular Physiology, 2020, 235, 6684-6696.	2.0	17
84	High GJB2 mRNA expression and its prognostic significance in lung adenocarcinoma: a study based on the TCGA database. Medicine (United States), 2020, 99, e19054.	0.4	8
85	<p><p>Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis</p></p>. OncoTargets and Therapy, 2020, Volume 13, 3085-3091.	1.0	25
86	HSP70 regulates cell proliferation and apoptosis in actinomycin-D-treated lung cancer cells. Translational Cancer Research, 2020, 9, 1167-1173.	0.4	1
87	MIR-301b-3p Promotes Lung Adenocarcinoma Cell Proliferation, Migration and Invasion by Targeting DLC1. Technology in Cancer Research and Treatment, 2021, 20, 153303382199003.	0.8	11
88	Deciphering the T790M/L858R-Selective Inhibition Mechanism of an Allosteric Inhibitor of EGFR: Insights from Molecular Simulations. ACS Chemical Neuroscience, 2021, 12, 462-472.	1.7	7
89	Pan-cancer investigation reveals mechanistic insights of planar cell polarity gene Fuz in carcinogenesis. Aging, 2021, 13, 7259-7283.	1.4	10
90	COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis. Frontiers in Pharmacology, 2021, 12, 619732.	1.6	13

#	ARTICLE	IF	CITATIONS
91	The long non-coding RNA SNHG4/microRNA-let-7e/KDM3A/p21 pathway is involved in the development of non-small cell lung cancer. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 634-645.	2.0	20
92	<scp>LncRNA FAM83A</scp> promotes <scp>lung adenocarcinoma</scp> progression by enhancing the <scp>pre</scp> mRNA</scp> stability of <scp>FAM83A</scp>. <i>Thoracic Cancer</i> , 2021, 12, 1495-1502.	0.8	18
93	Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies. <i>Health Services Research</i> , 2021, 56, 486-496.	1.0	3
94	Erlotinib Activates Different Cell Death Pathways in EGFR-mutant Lung Cancer Cells Grown in 3D <i>Versus</i> 2D Culture Systems. <i>Anticancer Research</i> , 2021, 41, 1261-1269.	0.5	5
95	Shifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer. <i>Cancers</i> , 2021, 13, 1316.	1.7	5
96	Body composition as a modulator of response to immunotherapy in lung cancer: time to deal with it. <i>ESMO Open</i> , 2021, 6, 100095.	2.0	8
97	Role of H2B mono-ubiquitination in the initiation and progression of cancer. <i>Bulletin Du Cancer</i> , 2021, 108, 385-398.	0.6	10
98	MCTS1 promotes the development of lung adenocarcinoma by regulating E2F1 expression. <i>Oncology Letters</i> , 2021, 22, 531.	0.8	5
99	cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 6125-6136.	1.6	3
101	Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy. <i>BMC Cancer</i> , 2021, 21, 752.	1.1	11
102	The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database. <i>BMC Cancer</i> , 2021, 21, 825.	1.1	22
103	Tumorigenic effect of <i>TERT</i> and its potential therapeutic target in NSCLC (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	10
105	Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges. <i>Cancer Treatment Reviews</i> , 2021, 99, 102250.	3.4	6
106	Overexpression of Teashirt Homolog 2 suppresses cell proliferation and predicts the favorable survival of Lung Adenocarcinoma. <i>International Journal of Medical Sciences</i> , 2021, 18, 1980-1989.	1.1	2
107	Phosphoproteomics Profiling to Identify Altered Signaling Pathways and Kinase-Targeted Cancer Therapies. <i>Methods in Molecular Biology</i> , 2020, 2051, 241-264.	0.4	3
108	Precision Medicine in Lung Cancer. <i>Molecular Pathology Library</i> , 2018, , 3-13.	0.1	1
109	Genomic landscape of lung adenocarcinoma in East Asians. <i>Nature Genetics</i> , 2020, 52, 177-186.	9.4	281
110	Gene-gene and gene-environment interaction data for platinum-based chemotherapy in non-small cell lung cancer. <i>Scientific Data</i> , 2018, 5, 180284.	2.4	9

#	ARTICLE	IF	CITATIONS
112	Establishment and Characterization of Pemetrexed-resistant NCI-H460/PMT Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 731-739.	0.9	5
114	TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10930.	1.8	16
115	Role of downregulated ADARB1 in lung squamous cell carcinoma. <i>Molecular Medicine Reports</i> , 2020, 21, 1517-1526.	1.1	4
117	Expression profile and prognostic values of STAT family members in non-small cell lung cancer. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 4866-4880.	0.0	14
121	Targeting Mitochondria as a Novel Disease-Modifying Therapeutic Strategy in Cancer. , 2022, , 241-262.		0
122	Evolution of small cell lung cancer tumor mutation: from molecular mechanisms to novel viewpoints. <i>Seminars in Cancer Biology</i> , 2022, 86, 346-355.	4.3	4
123	TRIM46 activates AKT/HK2 signaling by modifying PHLPP2 ubiquitylation to promote glycolysis and chemoresistance of lung cancer cells. <i>Cell Death and Disease</i> , 2022, 13, 285.	2.7	21
124	Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials. <i>Lung Cancer</i> , 2022, 167, 65-72.	0.9	6
125	DNA methylation molecular subtypes for prognosis prediction in lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2022, 22, 133.	0.8	4
126	Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer. <i>BMC Cancer</i> , 2021, 21, 1322.	1.1	7
127	LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer progression by targeting the miR-629-5p/TXNIP axis. <i>Annals of Translational Medicine</i> , 2021, 9, 1793-1793.	0.7	7
128	Current Research Progress of the Role of LncRNA LEF1-AS1 in a Variety of Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 750084.	1.8	3
132	Discoidin domain receptor 1 promotes lung adenocarcinoma migration via the AKT/snail signaling axis. <i>Molecular Biology Reports</i> , 2022, 49, 7275-7286.	1.0	5
133	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 172.	3.5	2
135	A Machine Learning and Radiomics Approach in Lung Cancer for Predicting Histological Subtype. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 5829.	1.3	6
136	Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
138	Clinical significance of STING expression and methylation in lung adenocarcinoma based on bioinformatics analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
139	Targeting Tumors Through Enhancers of Oxidative Stress. , 2022, , 3629-3648.		0

#	ARTICLE	IF	CITATIONS
140	Exosomeâ€delivered <sc>circSATB2</sc> targets the <sc>miR</sc> â€330â€5p/ <sc>PEAK1</sc> axis to regulate proliferation, migration and invasion of lung cancer cells. Thoracic Cancer, 0, , .	0.8	2
141	G protein subunit gamma 5 promotes the proliferation, metastasis and glycolysis of breast cancer cells through the Wnt/ <i>l</i> ² -catenin pathway. Anti-Cancer Drugs, 2022, 33, 1004-1011.	0.7	0
142	Comprehensive analyses of one-carbon metabolism related genes and their association with prognosis, tumor microenvironment, chemotherapy resistance and immunotherapy in lung adenocarcinoma. Frontiers in Molecular Biosciences, 0, 9, .	1.6	2
143	The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy. Seminars in Cancer Biology, 2022, 87, 160-169.	4.3	15
144	Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2023, 22, 264-273.	1.9	3
145	Mutation patterns and evolutionary action score of <sc><i>TP53</i></sc> enable identification of a patient population with poor prognosis in advanced nonâ€small cell lung cancer. Cancer Medicine, 2023, 12, 6649-6658.	1.3	2
146	Inâ€depth proteomics reveals the characteristic developmental profiles of early lung adenocarcinoma with epidermal growth factor receptor mutation. Cancer Medicine, 0, , .	1.3	1
147	Labyrinthin Expression Is Associated with Poor Prognosis in Patients with Non-Small-Cell Lung Cancer. Cancers, 2023, 15, 924.	1.7	1
148	An artificial intelligence networkâ€guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms. Cell Proliferation, 2023, 56, .	2.4	10